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S U M M A R Y
Generally, the primary lesion of a mold infection is in the airway, an extravascular site. Therefore, the
antifungal drug concentration at the actual tissue lesion of a mold infection is as important as in the
blood compartment. Although our antifungal armamentarium has expanded recently, polyenes are still
often needed in clinical practice because of their potent fungicidal activity and the rarity of resistance.
Nevertheless, the distribution of amphotericin B (AmB) in infected lung tissue has not yet been
evaluated. Using high-performance liquid chromatography analysis, we determined the concentrations
of AmB in plasma and infected and uninfected tissues of resected lung simultaneously, in a patient with
pulmonary aspergillosis treated with liposomal amphotericin B (L-AmB). The AmB concentration in the
infected lesion of the lung was approximately 5.2 times higher than that in plasma and 3.7 times higher
than in uninfected lung tissue. L-AmB accumulated in the infected lesion of the lung at a higher
concentration. Although our data are from only one patient, they may be useful in helping to develop
better strategies for the use of L-AmB against pulmonary fungal infections.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The lung is the most common site of aspergillosis, a life-
threatening disease with a dramatically increasing prevalence.1
Recently, we have been able to formulate several antifungal
strategies with new azoles and echinocandins, but polyenes
remain important in clinical practice because of their potent
fungicidal activity.2 However, the use of conventional amphoter-
icin B deoxycholate (CAB) is limited because it often causes renal
failure, hypokalemia, or infusion-related reactions.
Liposomal amphotericin B (L-AmB, AmBisome1; Gilead
Sciences, Sandimas, CA, USA) is a lipid formulation of amphotericin§ This study was presented in part, in Japanese, with the title ‘‘A case of
pulmonary aspergillosis associated with advanced esophageal cancer’’, at a poster
session of the 83rd Annual Meeting of the Japanese Association for Infectious
Diseases, held in Tokyo, April 23–24, 2009.
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average size of 60–100 nm.3 This drug exerts uniform fungicidal
activity and its toxicity-related events are signiﬁcantly reduced.2
The improved adverse drug event proﬁle and the contribution to
survival advantages are superior to those of CAB.2,4
The primary portal of entry of Aspergillus is the airway, an
extravascular site. Therefore, the antifungal drug concentration at
this actual site of fungal infection is as important as that in the
blood compartment. Smith et al. conjectured that more drug is
delivered to the mouse lung when it is infected with Aspergillus
fumigatus.5 It was presumed that AmB would accumulate more in
inﬂammatory lung tissue than at a normal lung site. However, to
our knowledge, no human data have been reported regarding drug
concentrations in infected and uninfected lung tissues in patients
treated with known doses of L-AmB.
In this report we describe a patient with pulmonary aspergil-
losis who was treated with L-AmB. We were able to evaluate the
concentrations of AmB in plasma, infected lung lesion, and
uninfected lung site at the same time.ses. Published by Elsevier Ltd. All rights reserved.
Fig. 1. The pulmonary aspergillosis lesion in the patient. (A) A trans-bronchial lung biopsy was performed from the right upper lobe. Thin separate hyphae showing
dichotomous branching are seen; GMS stain (400). (B) Two tissue samples were obtained from the resected lung. A sample was removed from the infected lesion
(arrowheads), and another was cut from the uninfected area (arrows).
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A 50-year-old male Japanese patient with advanced esophageal
cancer was referred to our hospital for anticancer chemotherapy.
He had multiple metastases, including lung and bone, and could
not be treated with surgery. Full examinations including broncho-
scopy were performed before chemotherapy, and a pulmonary
fungal infection in the right upper lobe of the lung was revealed.
Pathologically, brown-colored, thin separate hyphae showing
dichotomous branching and crystals of calcium oxalate were
observed. Using an in situ hybridization technique,6 this fungus
was revealed to be Aspergillus sp. From these ﬁndings, the causative
pathogen was determined to be A. niger (Fig. 1A). Cultures of sputa
and the biopsied specimen were negative. Renal and hepatic
functions were not impaired. The patient expressed a strong desire
to begin anticancer drugs; therefore, we started him on
voriconazole (400 mg/day) concurrently with his cancer treat-
ment.
After receiving the anticancer drugs, his body temperature rose
sharply (39.5 8C), and there were increases in his white blood cell
count (15.2  109/l) and C-reactive protein value (7.6 mg/dl). A
chest computed tomography scan revealed deterioration of the
aspergillosis. Based on these ﬁndings, the antifungal drug was
changed to L-AmB (150 mg/day (2.8 mg/kg) for the ﬁrst 4 days,
subsequently 250 mg/day (4.7 mg/kg)), and remission was quickly
achieved.
Twenty-two days after starting L-AmB, the patient again
developed a fever (39.2 8C), and radiological ﬁndings indicated
ingravescence of aspergillosis. Micafungin was added, but a drug
rash forced its discontinuation. Flucytosine (5-FC; 10 g/day) was
then added to the current antifungal therapy as a workaround.
Fortunately, he soon became afebrile with this antifungal
combination therapy.
In accordance with the patient’s unwavering demand for
continuance of his anticancer therapy, a right upper lobectomywas
performed to remove the infectious focus. The total amount of AmB
administered up until the surgery was 11 850 mg.
With written consent provided by the patient, we determined
the concentrations of AmB in plasma and lung tissues. Blood and
lung tissues were sampled during the operation. Blood samples
had been taken just before L-AmB administration, immediately
after administration was ﬁnished, and at the time of the rightupper lobe resection. The duration of L-AmB infusion was 3 h.
Plasma was separated by centrifugation. Two samples of lung
tissue (approximately 1 g, wet weight) were obtained, one from an
infected lesion and one from a distant, uninfected site that was
assessed macroscopically (Fig. 1B). Later, we examined adjacent
regions of each sample pathologically for conﬁrmation. Plasma and
tissue samples were frozen at 80 8C until the measurement of
AmB concentration.
The concentrations of the drug were evaluated by a high-
performance liquid chromatography (HPLC) method as previously
described by Takemoto et al.,7 with some modiﬁcation. The
internal standard solution was obtained by dissolving 1-amino-4-
nitronaphthalene (Sigma-Aldrich, Tokyo, Japan) in methanol at
30 mg/l. The plasma sample (150 ml) was extracted by the addition
of internal standard solution (150 ml) and methanol (500 ml).
Methanol was added for protein precipitation. After vortexing for
1 min and centrifuging at 10 000 g for 10 min, 200ml of super-
natants was collected and evaporated. The residue was re-
suspended in 100 ml of acetonitrile–2.5 mM EDTA (pH 5.0) 1:2
v/v and vortexed for 30 s. This sample, containing the total amount
of AmB, was submitted to HPLC analysis (50ml injected).
Lung tissue sample homogenization was carried out according
to the method described by Vogelsinger et al.,8 with some
modiﬁcation. Each lung tissue sample (0.15 g) supplemented with
methanol (1 ml) was homogenized in a homogenizer (IKA T10
basic ULTRA-TURRAX, IKA Japan Co., Ltd, Yamatokoriyama, Japan)
at 20 450 rpm. The tissue samples were used for preliminary and
other studies as well, and therefore not all of them could be used
repeatedly for evaluating the concentration. The homogenates
were extracted by a method similar to the plasma extraction
described above and submitted to HPLC analysis (50 ml injected).
The HPLC system consisted of LC-20AT solvent delivery pump
systems and an SPD-10Avp detector (Shimadzu Co., Kyoto, Japan).
The supernatants were separated on a CAPCELL PAK C18 SG120
reverse phase column (4.6 1  250 mm; Shiseido Co., Tokyo,
Japan). The mobile phase consisted of acetonitrile–2.5 mM EDTA
(pH 5.0) 1:2 v/v at a ﬂow rate of 1.0 ml/min. Under these
conditions, AmB and the internal standard were demonstrated at
retention times of approximately 13 and 20 min, respectively, and
were detected at 405 nm. The AmB concentration was determined
from the ratio between the area of AmB and that of the internal
standard. Standard curve samples were prepared with AmB
Table 1
Plasma and tissue concentrations of amphotericin B
Trough End of infusion Resection of lung
Plasma (mg/l) 32.8 60.3 60.8
Uninfected lung (mg/g) N/A N/A 86.2
Infected lung (mg/g) N/A N/A 316.0
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dissolved in methanol/dimethylsulfoxide 1:1 v/v and serially
diluted with methanol. The lower limit of detection in plasma was
0.1 mg/l and in lung tissue was 0.1 mg/g.
3. Results and discussion
The trough concentration of AmB in plasma was 32.8 mg/l, and
the concentration at the end of drug infusion was 60.3 mg/l. At the
time of lung lobe resection, the plasma concentration of the drug
was 60.8 mg/l (Table 1). These plasma concentration results are in
line with those reported by Walsh et al.9 In contrast, the AmB
concentration in the infected lung lesion was 316.0 mg/g. The
concentration of AmB in the uninfected lung was 86.2mg/g (Table
1). No metastasizing tumor was found in the resected lung tissue.
To the best of our knowledge, this is the ﬁrst report of a
comparison of drug concentrations in infected and uninfected
tissue in a patient treated with a speciﬁc dose of L-AmB. Paterson
et al., using HPLC, reported AmB levels in lung tissue infected
with Aspergillus sp. and in the background lung tissue of a
patient.10 This patient was treated with AmB for 28 days and died
from invasive aspergillosis. The concentrations in the infected
lesion and normal background lung were 0.1 and 0.67 mg/g,
respectively. However, this study did not mention the type of
drug formulation used (L-AmB or CAB) or the dose given to the
patient. In contrast, we have documented AmB concentrations in
infected and uninfected sites of the same lung of a patient treated
with known doses of L-AmB.
Collette et al. estimated that only approximately 18–40% of
tissue-bound AmB is bioactive.11 Thus, the increased antifungal
drug concentration at the actual lesion of a fungal infection, such as
in pulmonary aspergillosis, might be important. Moreover, the
lung architecture is mostly extravascular, and great emphasis has
recently been placed on antifungal activity at the tissue site of
infection.
The AmB concentration in infected lung tissue was approxi-
mately 5.2 times higher than that in plasma, whilst that in
uninfected lung tissuewas only 1.4 times higher. In general, L-AmB
is eliminated from the circulation primarily by the organs of the
reticulo-endothelial system, such as the liver and spleen.5,12 The
drug is effective at relatively lowdoses because of itsmechanismof
cellular delivery: tissue phospholipases cleave AmB, and the drug
then enters macrophages and fungus-infected cells.13 Smith et al.,
by immunohistochemical procedure, showed that L-AmB given to
mice was localized primarily within macrophages.5 Takemoto et
al. demonstrated that L-AmB itself was localized at the infected
sites in the lung of a mouse model of pulmonary aspergillosis.7
Thus, L-AmB can be expected to have the ability to accumulate and
achieve fungicidal concentrations at the site of fungal infection.14
Previous investigators have concluded that the administration
of L-AmB in experimental animals results in a higher Cmax value in
blood but in lower tissue concentrations comparedwith CAB.7,15 In
uninfected mice, the drug concentration in the lung was found to
be lower.5,15 The lung is not an organ of the reticulo-endothelial
system such as the liver or spleen, and L-AmB binds to lung tissue
at a low rate.
Some studies have determined the distribution of AmB in
autopsied human lung and other organs.3,8,11,16–18 The highestAmB concentrations have been found in liver and spleen, whereas
lesser amounts of the drug have been found accumulated in kidney
and lung. For example, the mean AmB tissue concentrations in the
liver, spleen, kidney, and lung from eight patients treatedwith CAB
(total doses of 101–2 688 mg) were 80.2, 50.9, 16.4, and 11.3mg/g,
respectively.16 More recently, themean concentrations from seven
patients given L-AmB (mean cumulative dose was 2 739 mg) were
documented as 102.8mg/g (liver), 60.3mg/g (spleen), 11.9 mg/g
(kidney), and 11.6 mg/g (lung).8 However, whether the autopsied
lung tissues in these studies were infected or not is unclear.
Demartini et al. reported the concentrations in plasma and lung
tissue in 18 patients with lung cancer after a single L-AmB
intravenous infusion; lung resection was done at 10–25 h after the
infusion.19 In their study, blood and lung tissue were sampled
during the operation and assayed for AmB concentrations.
Interestingly, the plasma AmB concentration progressively
decreased after completion of the infusion (from 3.4mg/ml to
1mg/ml), but the opposite occurred in lung tissue, where the AmB
concentration increased with time after the end of the infusion
(from 1mg/g to 2.5mg/g).
Meanwhile, in the same study, the tissue AmB concentrations
were much lower than those of our patient.19 L-AmB was given to
their patients only once at a lower dose (1.5 mg/kg), and no
infectious lesion was available in the resected lung. In our study, L-
AmBwas given daily for 49 days at higher doses (2.8 or 4.7 mg/kg),
and the drug concentrations in plasma and tissues were much
higher. Some studies have demonstrated that the total dose of L-
AmB is correlated with its concentration in the lung.17,18
Heinemann et al. reported that with higher cumulative doses of
L-AmB (1 200 mg) administered, higher concentrations of AmB
were detected in the lung tissue of patients (69.4mg/g), whereas
liver and spleen concentrations were found to remain relatively
unchanged.3 These ﬁndings suggest that the reticulo-endothelial
system, which is at least partly responsible for clearance of
liposomes from the circulation, transiently becomes saturated,
leading to more drug accumulating in the lung.3 Our result of
increased concentrations of AmB detected in the lung tissue of the
patient is consistent with these previous ﬁndings.
In our study, amuch higher concentration of AmBwas observed
in the infected lung lesion than in uninfected lung tissue. Although
the data described here are from only one patient, our results
support the hypothesis that L-AmB accumulates in lesions of
fungal infection.5,13,14 A methodological limitation is based on the
impossibility of assessing individual variability, because tissue
samples could be collected only once. Still, our results shed light on
the process of fungal infection affecting drug accumulation and
distribution. The degree to which our results can be generalized to
other patients with fungal infections is unclear, but this warrants
further examination.
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